论文部分内容阅读
Two novel rare earth tungstosilicic polyoxometalate containing 5-fluorouracil,K26(C4H4FN2O2)8Pr(SiW11O39)4·10H2O(FPSW) and K26(C4H4FN2O2)8Sm(SiW11O39)4·9H2O(FSSW),were synthesized and their structure were characterized by using elemental analysis,FTIR spectra,X-ray powder diffraction and TG.The antitumor activity tests of the compounds FPSW and FSSW were carried out by the methyl thiazolyl tetrazolium method in hepatocellular carcinoma cell HepG-2.The results showed that FPSW and FSSW could inhibit the HepG-2 cells in vitro significantly.The EC50 of FPSW and FSSW is 1.94×10-5 and 1.32×10-5 mol·L-1 respectively.The therapeutic index of FPSW and FSSW is 0.76 and 1.58 respectively.
Two novel rare earth tungstosilicic polyoxometalate containing 5-fluorouracil, K26 (C4H4FN2O2) 8Pr (SiW11O39) 4.10H2O (FPSW) and K26 (C4H4FN2O2) 8Sm (SiW11O39) 4 · 9H2O (FSSW) were synthesized and their structure were characterized by using elemental analysis, FTIR spectra, X-ray powder diffraction and TG. Antitumor activity tests of the compounds FPSW and FSSW were carried out by the methyl thiazolyl tetrazolium method in hepatocellular carcinoma cell HepG-2.The results showed that FPSW and FSSW could inhibit the HepG-2 cells in vitro significantly. EC50 of FPSW and FSSW was 1.94 × 10-5 and 1.32 × 10-5 mol·L-1 respectively. The therapeutic index of FPSW and FSSW was 0.76 and 1.58 respectively.